Insulet’s (PODD) Outperform Rating Reiterated at Raymond James
Insulet (NASDAQ:PODD – Get Free Report)‘s stock had its “outperform” rating restated by equities research analysts at Raymond ...
Piper Sandler Raises Insulet (NASDAQ:PODD) Price Target to $310.00
Insulet (NASDAQ:PODD – Get Free Report) had its price objective boosted by analysts at Piper Sandler from $285.00 to $310.00 ...
Insulet: Aiding Patients And Investors
Insulet's impressive growth with its Omnipod system, robust 2024 results, and surging valuation make it attractive. See more ...
Zacks.com on MSN2d
Insulet (PODD) Q4 Earnings and Revenues Top Estimates
Insulet (PODD) delivered earnings and revenue surprises of 9.52% and 2.73%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
Nasdaq2d
Notable Thursday Option Activity: NCLH, NOW, PODD
Below is a chart showing NOW's trailing twelve month trading history, with the $940 strike highlighted in orange: And Insulet Corp (Symbol: PODD) saw options trading volume of 2,567 contracts ...
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Insulet (PODD), Prothena (PRTA) and Travere Therapeutics (TVTX)
Analysts have been eager to weigh in on the Healthcare sector with new ratings on Insulet (PODD – Research Report), Prothena (PRTA – Research ...
Insulet: Q4 Earnings Snapshot
Insulet Corp. (PODD) on Thursday reported fourth-quarter profit of $100.7 million. On a per-share basis, the Acton, Massachusetts-based company said it had ...
Nasdaq2d
Insulet (PODD) Q4 Earnings and Revenues Top Estimates
Insulet (PODD) came out with quarterly earnings of $1.15 per share, beating the Zacks Consensus Estimate of $1.05 per share. This compares to earnings of $1.40 per share a year ago. These figures ...
Insulet beats quarterly profit estimates on insulin pump demand
Insulet reported a higher-than-expected profit in the fourth quarter on Thursday, driven by strong demand for its wearable insulin pumps.